Oncothyreon appoints Scott Peterson as Vice President of Research and Development

About this update from Cascade Copper Corp.

[{"type":"text","content":"\n\n\n\nSEATTLE, June 15 /CNW/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the\n"Company") today announced the appointment of Scott Peterson, Ph.D., as Vice\nPresident, Research and Development at Oncothyreon. In this position, Dr.\nPeterson will be responsible for overseeing those pre-clinical and\nnon-clinical research and development activities that will support the\nadvancement of the Company's pipeline of oncology product candidates into late\nphase clinical trials.\n\n\n"Scott brings an extensive background in cancer drug development to his\nnew role at Oncothyreon," said Robert L. Kirkman, M.D, President and Chief\nExecutive Officer. "His prior experience in small molecule drug development\nincludes work with protein kinases that will be especially relevant to PX-866,\nour inhibitor of PI-3 kinase for which we recently presented encouraging\npreliminary Phase 1 data at the American Society of Clinical Oncology. His\nbroad knowledge of cancer biology and drug targets will also be helpful in our\nongoing search for new product candidates. We are delighted to have him join\nour team."\n\n\n"I am very pleased to join Oncothyreon and excited about the opportunity\nto contribute to the further development of the Company's intriguing pipeline\nof targeted anti-cancer drug candidates," said Dr. Peterson. "I believe\nOncothyreon's diverse pipeline of therapeutic vaccines, such as Stimuvax(R),\nand targeted small molecules, including PX-866 and PX-478, create multiple\nopportunities for future success. I am looking forward to contributing to that\nfuture."\n\n\nDr. Peterson joins Oncothyreon from Zymogenetics, Inc., Seattle,\nWashington, where he has served as Director and Department Head, Oncology\nResearch, since 2007. In that capacity he has led a group of scientists\nengaged in antibody target discovery and drug candidate identification in\noncology. From 1999 until 2007 he held a variety of positions at ICOS\nCorporation in Bothell, Washington, most recently as a Principal Scientist in\nOncology Drug Discovery. At ICOS he was involved in both small molecule and\nantibody development. Dr. Peterson will assume his new role at Oncothyreon on\nAugust 1, 2009.\n\n\nAbout Oncothyreon\n\n\nOncothyreon is a biotechnology company specializing in the development of\ninnovative therapeut...

More updates from Cascade Copper Corp.